Psychedelic and MDMA-Related Adverse Effects—A Call for Action
Authors:
- 1 November 2024
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 5 (11) , e243630
Abstract
This Viewpoint discusses the need to better understand potential risks associated with psychedelic and 3,4-methylenedioxymethamphetamine (MDMA) use to ensure safe and ethical practice and identifies 4 key research goals.Keywords
This publication has 10 references indexed in Scilit:
- Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMAJournal of Affective Disorders, 2024
- A framework for assessment of adverse events occurring in psychedelic-assisted therapiesJournal of Psychopharmacology, 2024
- Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysisNeuropsychopharmacology, 2024
- Acute Adverse Effects of Therapeutic Doses of PsilocybinJAMA Network Open, 2024
- Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysisPsychiatry Research, 2024
- Use of Lysergic Acid Diethylamide by Major Depression StatusJAMA Psychiatry, 2024
- Extended difficulties following the use of psychedelic drugs: A mixed methods studyPLOS ONE, 2023
- Psychedelic Drug Legislative Reform and Legalization in the USJAMA Psychiatry, 2023
- Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic reviewJournal of Psychopharmacology, 2022
- A Classification of LSD ComplicationsPsychosomatics, 1966